Evidence map›Paper›PMID 29271260›Full record

ReviewExpert review of proteomics2018

Protein biomarkers for subtyping breast cancer and implications for future research.

Claudius Mueller, Amanda Haymond, Justin B Davis, Alexa Williams, Virginia Espina

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of proteomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Claudius Muellera Center for Applied Proteomics and Molecular Medicine , George Mason University , Manassas , VA , USA.
Amanda Haymonda Center for Applied Proteomics and Molecular Medicine , George Mason University , Manassas , VA , USA.
Justin B Davisa Center for Applied Proteomics and Molecular Medicine , George Mason University , Manassas , VA , USA.
Alexa Williamsa Center for Applied Proteomics and Molecular Medicine , George Mason University , Manassas , VA , USA.
Virginia Espinaa Center for Applied Proteomics and Molecular Medicine , George Mason University , Manassas , VA , USA.ORCID 0000-0001-5080-5972

Funding

Protein painting identifies therapeutic targets at protein-protein interfacesR33CA206937 · NCI · GEORGE MASON UNIVERSITY · PI LIOTTA, LANCE ALLEN · 2016 to 2018
$1.2M
NCI NIH HHS R33 CA206937
6 · The paper itself

Abstract

introductionBreast cancer subtypes are currently defined by a combination of morphologic, genomic, and proteomic characteristics. These subtypes provide a molecular portrait of the tumor that aids diagnosis, prognosis, and treatment escalation/de-escalation options. Gene expression signatures describing intrinsic breast cancer subtypes for predicting risk of recurrence have been rapidly adopted in the clinic. Despite the use of subtype classifications, many patients develop drug resistance, breast cancer recurrence, or therapy failure. Areas covered: This review provides a summary of immunohistochemistry, reverse phase protein array, mass spectrometry, and integrative studies that are revealing differences in biological functions within and between breast cancer subtypes. We conclude with a discussion of rigor and reproducibility for proteomic-based biomarker discovery. Expert commentary: Innovations in proteomics, including implementation of assay guidelines and standards, are facilitating refinement of breast cancer subtypes. Proteomic and phosphoproteomic information distinguish biologically functional subtypes, are predictive of recurrence, and indicate likelihood of drug resistance. Actionable, activated signal transduction pathways can now be quantified and characterized. Proteomic biomarker validation in large, well-designed studies should become a public health priority to capitalize on the wealth of information gleaned from the proteome.

Indexed as

Biomarkers, TumorBreast NeoplasmsFemaleHumansMass SpectrometryProteomicsBiomarkers, TumorBasal-likebiomarkerbreast cancerestrogen receptorHER2mass spectrometryprogesterone receptorreverse phase protein arraysignal transductiontriple negative breast cancer

Identifiers

PMID29271260
PMCPMC6104835

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.